α1-Antitrypsin (A1AT) purified from human plasma upregulates expression and release of angiopoietin-like protein 4 (Angptl4) in adherent human blood monocytes and in human lung microvascular endothelial cells, providing a mechanism for the broad immune-regulatory properties of A1AT independent of its anti-protease activity. Here we demonstrate that A1AT (Prolastin®), a potent inducer of Angptl4, contains significant quantities of the fatty acids (FA): linoleic (LA, C18:2) and oleic (OA, C18:1). However, only trace amounts of FAs were present in preparations that failed to increase Angplt4 expression, for example A1AT (Zemaira) or M-type A1AT purified by affinity chromatography. FA pull-down assays with western blot analysis revealed a FA-binding ability of A1AT. In human blood adherent monocytes A1AT‐FA conjugates up-regulated expression of Angptl4 (54.9-fold, p<0.001), fatty acid binding protein 4 (FABP4) (11.4-fold, p<0.001) and to a lesser degree, fatty acid translocase (CD36) (3.1-fold, p<0.001) relative to A1AT devoid of FA (A1AT‐0). These latter effects of A1AT-FA were blocked by inhibitors of PPARβ/δ (ST247) and PPARγ (GW9662). When compared to controls, cell pre-treatment with ST247 diminished the effect of A1AT-LA on Angptl4 mRNA (11.6- vs 4.1-fold, p<0.001) and FABP4 mRNA (5.4-vs 2.8-fold, p<0.001). Similarly, pre-incubation of cells with GW9662 inhibited inducing effect of A1AT-LA on Angptl4 mRNA (by 2-fold, p<0.001) and FABP4 mRNA (by 3-fold, p<0.001). Thus, A1AT binds to FA, and it is this form of A1AT that induces Angptl4 and FABP4 expression via a PPARs-dependent pathway. These findings provide a mechanism for the unexplored area of A1AT biology independent of its anti-protease properties.